FORMA Therapeutics announced today that it has entered into a license and option agreement through the Novartis Option Fund. Under the terms of the agreement, FORMA will leverage its transformative biology and chemistry platform to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology. The agreement includes an upfront fee and potential milestones …
View original here:
FORMA Therapeutics Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions (Centre Daily Times)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.